Terumo Aortic discovered breakthrough RelayBranch Thoracic Stent-Graft System.
The system is applicable for patients with thoracic aortic arch pathologies which requires treatment that includes coverage of the innominate and left common carotid arteries.
The RelayBranch Thoracic Stent-Graft System system consists of main body graft which is positioned in the ascending aorta and consists of two anterograde tunnels giving the way to a large cannulation window. Branch grafts are then placed the anterograde tunnels for both the innominate artery and left common carotid artery.
The RelayBranch Thoracic Stent-Graft System proves to be an effective treatment for patients who are at high risk of open surgical repair where currently no alternative therapies are available.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation for the RelayBranch Thoracic Stent-Graft System.
US physicians will be able to treat patients with a less invasive treatment option by making use of innovative technology of the RelayBranch endovascular device.